Early observations and pilot data that first suggested a new direction
Angelita Habr-Gama's pioneering work from Sao Paulo, Brazil, first demonstrated that deferral of surgery was feasible in rectal cancer patients achieving complete clinical response (cCR) to chemoradiation. In the landmark 2004 report of 265 patients, 71 (27%) achieved cCR and entered a surveillance protocol. With mean 57.3-month follow-up, only 2 patients developed local regrowth and 3 developed distant metastases. Five-year overall survival was 100% and disease-free survival 92%. These results challenged the dogma that all rectal cancer patients required radical surgery after neoadjuvant therapy.
Landmark RCTs and pivotal trials that established the evidence base
The International Watch & Wait Database (IWWD), published in 2018, provided the largest multicenter validation of the watch-and-wait approach. Across 47 institutions in 15 countries, 1,009 patients managed with watch-and-wait were analyzed. Local regrowth occurred predominantly within the first 2 years and within the bowel wall, emphasizing the importance of endoscopic surveillance. Critically, unsalvageable disease after regrowth was rare. The OPRA trial (2022) then demonstrated that total neoadjuvant therapy (TNT) combined with a watch-and-wait strategy achieved organ preservation in 46% of patients with locally advanced rectal cancer without compromising disease-free survival.
Follow-up studies, subgroup analyses, and real-world validation
Long-term OPRA data (median 5.1-year follow-up) confirmed the durability of the approach, with most regrowths occurring within the first 2 years and salvage surgery remaining feasible. The convergent evidence from the IWWD, OPRA, and multiple institutional series established that watch-and-wait is not simply observation but a structured surveillance strategy requiring endoscopy, MRI, and clinical assessment at defined intervals. Patient selection, response assessment timing, and the definition of complete clinical response became central to standardizing the approach.
Guidelines
Integration into clinical practice guidelines and recommendations
NCCN and ESMO guidelines now recognize watch-and-wait as a reasonable option for patients achieving complete clinical response after neoadjuvant therapy, with the caveat that rigorous surveillance protocols and patient counseling are essential. The approach is increasingly incorporated into institutional protocols, particularly when combined with total neoadjuvant therapy.
NCCN
Watch-and-wait acceptable for clinical complete response after neoadjuvant therapy with structured surveillance
ESMO
Organ preservation strategy reasonable in complete responders; multidisciplinary team assessment essential
Now
Current standard of care and ongoing research directions
Watch-and-wait has transitioned from a provocative concept to an accepted component of rectal cancer management. The approach is best established following total neoadjuvant therapy, where complete clinical response rates are highest. Active research focuses on improving response prediction using artificial intelligence-enhanced MRI, circulating tumor DNA for early regrowth detection, and standardizing surveillance protocols. The question has shifted from whether watch-and-wait is safe to how to maximize complete response rates and optimize patient selection.
What is the watch-and-wait approach for rectal cancer?+
Watch-and-wait is an organ preservation strategy where patients achieving a complete clinical response to neoadjuvant chemoradiation or total neoadjuvant therapy undergo structured surveillance instead of immediate radical surgery. Pioneered by Habr-Gama (2004), it was validated by the International Watch & Wait Database (1,009 patients from 47 institutions) and the OPRA trial (324 patients). The approach preserves the rectum in approximately 46% of patients without compromising disease-free survival.
What happens if the cancer regrows during watch-and-wait?+
Based on IWWD data, local regrowth occurs predominantly within the first 2 years and is typically confined to the bowel wall. Salvage surgery (usually TME) remains feasible in the vast majority of cases, with unsalvageable disease being rare. This is why structured endoscopic and MRI surveillance at defined intervals is critical during the watch-and-wait period.
